From Morningstar: 2024-06-04 05:43:00

Morningstar analysts maintain GlaxoSmithKline’s Fair Value Estimate at £22.00 despite increased litigation risk over alleged Zantac cancer links. GSK is confident in appeal process due to various factors including FDA clearance for Zantac and favorable rulings in recent litigation cases.

Damien Conover, Director of Healthcare Equity Research at Morningstar, predicts Zantac litigation costs for GSK will amount to $1 billion (£781 million). If appeal fails, costs may rise due to legal expenses and settlements, but a positive ruling could dismiss plaintiffs’ cases quickly. Despite uncertainty, Conover remains optimistic about GSK’s future.



Read more at Morningstar: No Change to GSK Shares’ Fair Value Estimate…